Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab vs. Pembrolizumab/Cetuximab in Platinum-Refractory Recurrent or Metastatic HNSCC
NCT06589804Phase 3Recruiting
- Sponsor
- National Cancer Institute
- Start
- Mar 2025
- Primary completion
- Dec 2032
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of KL-140 in head and neck squamous cell carcinoma (HNSCC), sponsored by National Cancer Institute. Started Mar 2025; status: recruiting.
02
Drugs
KL-140
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06589804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06589804.